CIK 0001781174 · <br>Emerging growth company
Acrivon Therapeutics, Inc.
Sign in to watch- Ticker
- ACRV
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Entity type
- operating
- EIN
- 825125532
- Phone
- 617-207-8979
- Business address
- 480 ARSENAL WAY, SUITE 100, WATERTOWN, MA, 02472
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $38,534
- in 8 filings
Net −$38,534. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
- Blume-Jensen Peter −$34K President and CEO sold <1% of stake
- Miller Mary −$2K Chief Legal Officer sold 1% of stake
- Devroe Eric −$1K Chief Operating Officer sold <1% of stake
- Gamelin Erick −$804 Chief Development Officer sold <1% of stake
- Peterson Katharine −$203 Chief Accounting Officer sold <1% of stake
Reading 84 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-04-25 | PERCEPTIVE ADVISORS LLC 10% owner | Sale | −1,054,669 | $1.95 | $2.1M | 4,306,189 |
| 2025-04-17 | Miller Mary Chief Legal Officer | Shares withheld for taxes | −558 | $1.81 | $1K | 36,507 |
| 2025-04-01 | Miller Mary Chief Legal Officer | Grant or award · Stock Option (Right to Buy) | +15,616 | 15,616 | ||
| 2025-04-01 | Levy Adam D. Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +35,209 | 35,209 | ||
| 2025-03-01 | Peterson Katharine Chief Accounting Officer | Grant or award · Stock Option (Right to Buy) | +31,900 | 31,900 | ||
| 2025-03-01 | Miller Mary Chief Legal Officer | Grant or award · Stock Option (Right to Buy) | +93,693 | 93,693 | ||
| 2025-03-01 | Holm-Jorgensen Rasmus Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +109,309 | 109,309 | ||
| 2025-03-01 | Gamelin Erick Chief Development Officer | Grant or award · Stock Option (Right to Buy) | +78,078 | 78,078 | ||
| 2025-03-01 | Devroe Eric Chief Operating Officer | Grant or award · Stock Option (Right to Buy) | +140,540 | 140,540 | ||
| 2025-03-01 | Cuillerot Jean-Marie Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +78,078 | 78,078 | ||
| 2025-03-01 | Blume-Jensen Peter President and CEO | Grant or award · Stock Option (Right to Buy) | +390,390 | 390,390 | ||
| 2025-03-01 | Blume-Jensen Peter President and CEO | Grant or award · Stock Option (Right to Buy) | +140,540 | 140,540 | ||
| 2025-02-21 | Blume-Jensen Peter President and CEO | Shares withheld for taxes | −19,904 | $5.54 | $110K | 2,285,781 |
Page 6 of 6 · 113 trades